DISTRICT OF COLUMBIA: Members of Congress have re-authorized a federal provision prohibiting the Justice Department from interfering in state-authorized medical cannabis programs. The provision, known as the Rohrabacher-Farr amendment, was included in short-term spending legislation, House Resolution 2028, and will expire on April 28, 2017. Initially enacted by Congress in 2014, the amendment maintains that federal funds Read the full article…
You may also like
Nevada: As of January Most employers in Nevada can no longer...view more
Just a quick reminder of legislation signed into law mid 2019 by the state’s governor and came...view more
420 Investor Daily Publishes Simple Guide To Cannabis Laws In...view more
If you are looking for a quick overview of where we are January 2020 this is as good a starting...view more
California Cannabis Delivery Law Challenge to Be Weighed by...view more
Last year, the California Bureau of Cannabis Control adopted a controversial policy allowing...view more
Newsweek: Congress Silently Killed Several Cannabis Reforms This...view more
Is it just us ? But it’s intriguing that this happens just as the the bottom falls out of...view more
New Jersey: Lawsuits aimed at halting award of new medical...view more
NJ .com reports The New Jersey state Department of Health must halt its review of nearly 150...view more
Pasadena Wins in Cannabis Ballot Lawsuit Against… Itself
The City of Pasadena sued itself over a controversial cannabis ballot initiative – and won. The...view more
Can Trump Ignore Medical Marijuana Protections Passed By...view more
In a recent statement on a large-scale federal funding bill that President Donald Trump signed into...view more
MORE Act Passes in Historic Vote
The House Judiciary Committee approved a 2019 bill to decriminalize marijuana at the federal level...view more
MORE Act Passes House Judiciary Committee
According to a press release published by the National Cannabis Industry Association (NCIA), the...view more
Cannabis Patent Litigation: Remedies for Patent Infringement
Continuing our discussion from last week, we received a few follow-up questions on whether patent...view more